AR‐V7 as a Biomarker for Resistance to Treatment with Abiraterone/Enzalutamide in Three Latin American Countries: A Hypothetical Cost‐Saving Analysis

BACKGROUND: Prostate cancer is the most incident and one of the deadliest male cancers in Latin America. Treatment for patients with metastatic castration‐resistant prostate cancer (mCRPC) includes androgen receptor signaling inhibitors such as abiraterone and enzalutamide, for which androgen recept...

Descripción completa

Detalles Bibliográficos
Autores principales: Pacheco‐Orozco, Rafael Adrián, Montealegre‐Páez, Lorena, Cayol, Federico, Martínez‐Gregorio, Héctor, Oliver, Javier, Frecha, Cecilia, Vaca‐Paniagua, Felipe, Perdomo, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Global Health and Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108055/
https://www.ncbi.nlm.nih.gov/pubmed/32721059
http://dx.doi.org/10.1634/theoncologist.2020-0043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108055/
https://www.ncbi.nlm.nih.gov/pubmed/32721059
http://dx.doi.org/10.1634/theoncologist.2020-0043

Ejemplares similares